Compare Levi Strauss & Co. (LEVI) vs 10X Genomics Inc (TXG) Price & Performance

Levi Strauss & Co. (LEVI) trades at $23.59, down 3.32% over 24 hours, amid a recent cybersecurity incident disclosed on August 7, 2026. The stock shows strong fundamentals with a P/E of 16.24, robust gross margin of 61.72%, and consistent earnings beats in recent quarters. Technical indicators are bearish, with support near $23, while analyst consensus remains bullish with a $27.88 price target.

The outlook for LEVI is positive due to solid DTC growth and raised 2026 guidance, but risks include cybersecurity concerns and tariff pressures. Earnings momentum and a reasonable valuation support upside potential, though near-term volatility may persist from the security breach and market reactions.

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.